The Thévenin Lab at Lehigh University
  • Twitter

Welcome to the Thévenin Lab

Membrane biochemistry and targeted drug delivery

The research conducted in our group lies at the interface of cell biology, chemistry, biochemistry, and biophysics, with a particular focus on problems in cancer drug delivery and membrane protein cell signaling. As such, our work is applied, fundamental, and highly interdisciplinary. Current research programs are organized around two main areas:

  • Understanding how transmembrane oligomerization control membrane receptors activity and cell signaling.

  • Developing novel strategies to specifically target and deliver  therapeutics to cancer cells and tumors.

  • Identifying and quantifying the biophysical parameters governing flow-mediated transport of membrane proteins.

As such, our work is applied, fundamental, highly interdisciplinary, and draws upon areas such as peptide and protein chemistry, biochemistry, biophysics, molecular, cellular and structural biology, cell signaling, and oncology.

Ongoing projects are aimed at selectively targeting and delivering immunological agents and bacteria to tumors, and at identifying the structural requirements for the dimerization of an understudied but essential family of membrane receptors, the receptor protein-tyrosine phosphatases (RPTPs).

We are currently funded by the NIH (R01GM139998, R01GM14332, and R01GM145991).

  • Learn More

Menu

  • Homepage
  • Research
  • The Group
    • Members
    • Group Photos
    • Other Photos
  • Publications
  • News

Get in touch

Don't hesitate to contact us. There are always openings for motivated undergraduate and graduate students. Please, email for more information about availability and specific research projects.

  • damien.thevenin@lehigh.edu
  • (610) 758-2886 (D. Thévenin)
    (610) 758-4969 (Lab)
  • Department of Chemistry
    Lehigh University
    Seeley Mudd Building
    6 E. Packer Avenue
    Bethlehem, PA 18015

Design: Damien Thévenin and HTML5 UP. Photos: Christa Neu. Illustration: Antti Uotila.